ClinicalTrials.gg
CompletedNCT01229449Updated Sep 17, 2018Results posted

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

A Phase 3 interventional study of Ibuprofen/acetaminophen and Ibuprofen/acetaminophen (higher dose) in Post-operative Pain, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.

Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
678
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.

Enrollment
4th of 56
678 · median 100
Started
2009
with 2 others
Phase 3
7 of 56
none open now
Registered
4th of 56
by date

Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 7 in phase 3, and was the 4th registered.

Pain, Postoperative

5,662 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing ibuprofen in Pain, Postoperative, or all of them as a file.
02

Study summary

The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.

Read the detailed description

RB has developed a fixed-dose combination of ibuprofen and acetaminophen (paracetamol). Since the pharmacological actions of ibuprofen and acetaminophen (paracetamol) differ in their site and mode of action, the combination would be expected to be more effective than either active alone, given that pain is multi-factorial with different mediators.

The purpose of this study was to compare the efficacy and tolerability of ibuprofen/acetaminophen (paracetamol) combination with leading market analgesics.

The efficacy and tolerability was assessed in terms of total analgesic effect, peak analgesic effect, onset and duration of action and the subject's overall assessment of the study medication.

03

Conditions studied

  • Post-operative Pain

Keywords

  • Dental pain
  • Ibuprofen
  • Acetaminophen
  • Nurofen Plus®
  • Panadeine® Extra
  • Paracetamol
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

Experiencing moderate to severe pain after extraction of impacted third molars

Main Exclusion Criteria:

Any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability Any condition that would render the subject unsuitable to receive an NSAID, acetaminophen or codeine

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
678 participants (actual)

Study arms

  • Experimental
    Ibuprofen/acetaminophen (lower dose)

    One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet

    Drug: Ibuprofen/acetaminophen

  • Experimental
    Ibuprofen/acetaminophen (higher dose)

    Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg

    Drug: Ibuprofen/acetaminophen (higher dose)

  • Active comparator
    Nurofen Plus®

    Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)

    Drug: Nurofen Plus®

  • Active comparator
    Panadeine® Extra

    Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)

    Drug: Panadeine® Extra

  • Placebo comparator
    Placebo

    Two placebo tablets

    Drug: Placebo

Interventions

  • DrugIbuprofen/acetaminophen

    Drug pages: Ibuprofen · Acetaminophen

    One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water

    Also known as: Ibuprofen/paracetamol (lower dose)

  • DrugIbuprofen/acetaminophen (higher dose)

    Drug pages: Ibuprofen · Acetaminophen

    Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water

    Also known as: Ibuprofen/Paracetamol

  • DrugNurofen Plus®

    Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water

    Also known as: Ibuprofen/Codeine

  • DrugPanadeine® Extra

    Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water

    Also known as: Acetaminophen/codeine, Paracetamol/codeine

  • DrugPlacebo

    Two placebo tablets, single dose taken orally with 300 ml water

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)

    SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

    Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

Secondary outcomes

  1. Change From Baseline in AUC (0-8h) of SPRID

    SPRID 0-8h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0 mm = No pain and 100 mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

    Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose

  2. Change From Baseline in AUC for Pain Intensity Difference Scores (SPID)

    Sum of Pain Intensity Difference (SPID) was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Score range: 0mm = No pain and 100mm = Worst pain. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?'

    Time frame: 0-4, 0-6, 0-8 and 0-12 hours

  3. Change From Baseline in AUC of Pain Relief Scores (TOTPAR)

    Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.

    Time frame: 0-4, 0-6, 0-8 and 0-12 hours

  4. Change From Baseline in AUC of Individual Reading Pain Intensity and Relief Scores (SPRID)

    SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours

  5. Individual Pain Intensity Differences (Ordinal)

    Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours

  6. Individual Pain Intensity Differences Visual Analogue Scale (VAS)

    Pain Intensity (PI) VAS was measured using a horizontal 100-mm VAS ranging 0 mm = 'No Pain' as the left anchor and 100 mm = 'Worst Pain' as the right anchor, labelled by the subject marking the VAS line in the pain assessment questionnaire in response to the instruction 'Please indicate with a line on the scale below your pain at this time.'

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours

  7. Change From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal)

    Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.

    Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  8. Change From Baseline in Peak Pain Relief (PR)

    Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.

    Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  9. Subjects' Overall Assessment of the Study Medication Assessed at 12 Hours or Just Before Administration of Rescue Medication

    Subject's Overall Assessment measured by subject ticking the appropriate box in response to the question 'How effective do you think the study medication is as a treatment for pain?' Subject's Overall Assessment rated on a five-point ordinal scale: 1 = Poor, 2 = Fair, 3 = Good, 4 = Very good, and 5 = Excellent.

    Time frame: At 12 hours

07

Results

Posted Sep 17, 2018

Participant flow

Subjects were recruited in three centres, Salt Lake City (243 subjects randomised), San Marcos (229 subjects randomised) and Austin (206 subjects randomised)

Participant flow — Overall Study
MilestoneIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
Started17316816911355
Completed17216416711254
Not completed14211
Withdrew: Withdrawal by subject03011
Withdrew: Lost to follow-up11100
Withdrew: Physician decision00100

Outcome measures

PrimaryChange From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)

SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

Time frame:
0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Mean · units on a scale*hour
Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)
units on a scale*hourIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)2.68 ± 1.593.30 ± 1.672.62 ± 1.731.93 ± 1.510.54 ± 1.37
Statistical analysis
  • Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) vs Placebo · ANOVA · p = <0.0001
  • Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) vs Panadeine® Extra · ANOVA · p = <0.0001
  • Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) vs Nurofen Plus® · ANOVA · p = 0.0001
  • Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) vs Panadeine® Extra · ANOVA · p = 0.0001
  • Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) vs Nurofen Plus® · ANOVA · p = 0.72
  • Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) vs Placebo · ANOVA · p = <0.0001
  • Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) vs Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) · ANOVA · p = 0.0005
  • Nurofen Plus® vs Panadeine® Extra · ANOVA · p = 0.0005
  • Nurofen Plus® vs Placebo · ANOVA · p = <0.0001
  • Panadeine® Extra vs Placebo · ANOVA · p = <0.0001
SecondaryChange From Baseline in AUC (0-8h) of SPRID

SPRID 0-8h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0 mm = No pain and 100 mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

Time frame:
0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose
Reported as:
Mean · units on a scale*hour
Change From Baseline in AUC (0-8h) of SPRID
units on a scale*hourIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
0-4h3.65 ± 1.603.95 ± 1.523.44 ± 1.723.19 ± 1.610.61 ± 1.26
0-6h3.66 ± 1.684.06 ± 1.643.45 ± 1.822.86 ± 1.620.60 ± 1.32
0-8h3.39 ± 1.713.91 ± 1.693.22 ± 1.852.48 ± 1.570.57 ± 1.31
SecondaryChange From Baseline in AUC for Pain Intensity Difference Scores (SPID)

Sum of Pain Intensity Difference (SPID) was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Score range: 0mm = No pain and 100mm = Worst pain. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?'

Time frame:
0-4, 0-6, 0-8 and 0-12 hours
Reported as:
Mean · units on a scale*hour
Change From Baseline in AUC for Pain Intensity Difference Scores (SPID)
units on a scale*hourIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
0-4h1.32 ± 0.731.46 ± 0.721.23 ± 0.751.13 ± 0.700.18 ± 0.53
0-6h1.32 ± 0.741.50 ± 0.751.23 ± 0.761.01 ± 0.670.19 ± 0.53
0-8h1.21 ± 0.731.43 ± 0.751.14 ± 0.750.87 ± 0.630.19 ± 0.53
0-12h0.94 ± 0.641.18 ± 0.690.91 ± 0.670.67 ± 0.570.19 ± 0.56
SecondaryChange From Baseline in AUC of Pain Relief Scores (TOTPAR)

Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.

Time frame:
0-4, 0-6, 0-8 and 0-12 hours
Reported as:
Mean · units on a scale*hour
Change From Baseline in AUC of Pain Relief Scores (TOTPAR)
units on a scale*hourIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
0-4h2.33 ± 0.962.48 ± 0.902.20 ± 1.042.05 ± 1.000.42 ± 0.77
0-6h2.34 ± 1.022.56 ± 0.982.22 ± 1.121.85 ± 1.030.41 ± 0.82
0-8h2.18 ± 1.052.48 ± 1.032.08 ± 1.151.61 ± 1.010.38 ± 0.81
0-12h1.73 ± 1.012.12 ± 1.061.70 ± 1.111.27 ± 0.980.34 ± 0.82
SecondaryChange From Baseline in AUC of Individual Reading Pain Intensity and Relief Scores (SPRID)

SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Reported as:
Mean · units on a scale
Change From Baseline in AUC of Individual Reading Pain Intensity and Relief Scores (SPRID)
units on a scaleIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
15 minutes1.12 ± 1.211.29 ± 1.380.78 ± 1.221.01 ± 1.400.29 ± 0.74
30 minutes2.49 ± 1.632.79 ± 1.622.08 ± 1.712.62 ± 1.830.58 ± 1.13
45 minutes3.20 ± 1.723.52 ± 1.642.92 ± 1.843.39 ± 1.800.65 ± 1.38
60 minutes3.71 ± 1.834.04 ± 1.663.49 ± 1.983.81 ± 1.830.71 ± 1.49
90 minutes4.12 ± 1.824.44 ± 1.693.92 ± 2.063.96 ± 1.770.60 ± 1.56
2 hours4.28 ± 1.954.51 ± 1.804.17 ± 2.143.91 ± 1.900.67 ± 1.43
3 hours4.18 ± 2.064.53 ± 1.954.02 ± 2.143.31 ± 2.131.66 ± 0.00
4 hours4.08 ± 2.094.46 ± 2.093.78 ± 2.312.79 ± 2.210.64 ± 1.65
5 hours3.77 ± 2.214.36 ± 2.123.52 ± 2.402.23 ± 2.200.60 ± 1.59
6 hours3.06 ± 2.343.98 ± 2.242.98 ± 2.471.70 ± 2.160.53 ± 1.56
7 hours2.56 ± 2.373.51 ± 2.402.54 ± 2.501.31 ± 2.000.45 ± 1.45
8 hours2.09 ± 2.312.79 ± 2.492.08 ± 2.381.02 ± 1.920.40 ± 1.30
9 hours1.57 ± 2.202.53 ± 2.471.68 ± 2.200.91 ± 1.870.47 ± 1.59
10 hours1.21 ± 2.022.04 ± 2.341.30 ± 2.060.81 ± 1.840.49 ± 1.62
11 hours0.90 ± 1.831.63 ± 2.241.12 ± 2.020.76 ± 1.770.49 ± 1.62
12 hours0.69 ± 1.641.34 ± 2.140.96 ± 1.850.74 ± 1.760.49 ± 1.62
SecondaryIndividual Pain Intensity Differences (Ordinal)

Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Reported as:
Mean · units on a scale
Individual Pain Intensity Differences (Ordinal)
units on a scaleIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
15 minutes0.40 ± 0.570.46 ± 0.640.23 ± 0.580.31 ± 0.640.09 ± 0.40
30 minutes0.94 ± 0.761.03 ± 0.740.73 ± 0.800.95 ± 0.830.15 ± 0.56
45 minutes1.14 ± 0.761.27 ± 0.761.04 ± 0.801.19 ± 0.830.16 ± 0.63
60 minutes1.31 ± 0.851.48 ± 0.791.24 ± 0.871.35 ± 0.850.22 ± 0.79
90 minutes1.49 ± 0.831.61 ± 0.841.40 ± 0.921.42 ± 0.830.11 ± 0.81
2 hours1.54 ± 0.891.69 ± 0.871.52 ± 0.941.41 ± 0.840.24 ± 0.54
3 hours1.54 ± 0.911.70 ± 0.891.46 ± 0.931.19 ± 0.870.22 ± 0.66
4 hours1.49 ± 0.911.68 ± 0.941.36 ± 0.950.96 ± 0.900.24 ± 0.64
5 hours1.35 ± 0.931.60 ± 0.931.24 ± 0.960.79 ± 0.880.22 ± 0.63
6 hours1.07 ± 0.931.44 ± 0.931.04 ± 0.950.58 ± 0.820.20 ± 0.62
7 hours0.89 ± 0.931.22 ± 0.980.88 ± 0.960.44 ± 0.740.18 ± 0.61
8 hours0.71 ± 0.890.96 ± 0.960.72 ± 0.890.33 ± 0.710.16 ± 0.54
9 hours0.53 ± 0.800.86 ± 0.940.55 ± 0.800.29 ± 0.680.20 ± 0.68
10 hours0.40 ± 0.740.67 ± 0.870.43 ± 0.750.27 ± 0.670.20 ± 0.68
11 hours0.27 ± 0.640.52 ± 0.800.36 ± 0.730.24 ± 0.630.20 ± 0.68
12 hours0.21 ± 0.570.42 ± 0.780.30 ± 0.630.25 ± 0.630.20 ± 0.68
SecondaryIndividual Pain Intensity Differences Visual Analogue Scale (VAS)

Pain Intensity (PI) VAS was measured using a horizontal 100-mm VAS ranging 0 mm = 'No Pain' as the left anchor and 100 mm = 'Worst Pain' as the right anchor, labelled by the subject marking the VAS line in the pain assessment questionnaire in response to the instruction 'Please indicate with a line on the scale below your pain at this time.'

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Reported as:
Mean · units on a scale
Individual Pain Intensity Differences Visual Analogue Scale (VAS)
units on a scaleIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
15 minutes9.0 ± 13.710.5 ± 16.34.5 ± 14.18.7 ± 16.60.4 ± 13.1
30 minutes22.8 ± 21.426.2 ± 21.517.7 ± 22.523.9 ± 23.92.2 ± 16.7
45 minutes32.5 ± 23.837.5 ± 24.028.3 ± 25.734.3 ± 25.70.9 ± 18.8
60 minutes40.3 ± 25.546.3 ± 24.436.6 ± 28.741.5 ± 27.11.8 ± 19.3
90 minutes48.3 ± 25.852.5 ± 24.843.7 ± 28.244.6 ± 25.90.9 ± 22.6
2 hours50.6 ± 26.654.9 ± 25.747.3 ± 29.345.2 ± 27.95.0 ± 18.2
3 hours51.0 ± 27.155.9 ± 25.548.0 ± 29.338.9 ± 29.96.1 ± 21.3
4 hours50.2 ± 27.855.5 ± 26.445.6 ± 29.932.9 ± 29.47.2 ± 20.3
5 hours45.4 ± 28.752.8 ± 26.742.5 ± 30.425.9 ± 29.27.2 ± 19.8
6 hours36.6 ± 30.247.9 ± 27.835.6 ± 30.618.4 ± 27.26.5 ± 19.7
7 hours30.9 ± 30.641.0 ± 29.829.7 ± 30.815.4 ± 25.25.8 ± 18.8
8 hours25.0 ± 28.933.8 ± 30.824.4 ± 29.811.7 ± 24.45.1 ± 17.2
9 hours17.7 ± 26.429.6 ± 30.318.4 ± 27.210.8 ± 22.95.6 ± 19.4
10 hours14.1 ± 25.223.7 ± 29.114.9 ± 25.39.7 ± 22.96.2 ± 20.3
11 hours9.4 ± 21.218.7 ± 27.212.8 ± 24.79.8 ± 23.26.2 ± 20.1
12 hours8.0 ± 20.415.1 ± 25.511.0 ± 22.99.3 ± 22.16.4 ± 20.8
SecondaryChange From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal)

Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.

Time frame:
0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Mean · units on a scale
Change From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal)
units on a scaleIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
Change From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal)1.78 ± 0.831.93 ± 0.811.74 ± 0.871.63 ± 0.770.60 ± 0.87
SecondaryChange From Baseline in Peak Pain Relief (PR)

Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.

Time frame:
0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Mean · units on a scale
Change From Baseline in Peak Pain Relief (PR)
units on a scaleIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
Change From Baseline in Peak Pain Relief (PR)3.06 ± 1.003.25 ± 0.892.98 ± 1.112.88 ± 1.000.96 ± 1.15
SecondarySubjects' Overall Assessment of the Study Medication Assessed at 12 Hours or Just Before Administration of Rescue Medication

Subject's Overall Assessment measured by subject ticking the appropriate box in response to the question 'How effective do you think the study medication is as a treatment for pain?' Subject's Overall Assessment rated on a five-point ordinal scale: 1 = Poor, 2 = Fair, 3 = Good, 4 = Very good, and 5 = Excellent.

Time frame:
At 12 hours
Reported as:
Count of participants · Participants
Subjects' Overall Assessment of the Study Medication Assessed at 12 Hours or Just Before Administration of Rescue Medication
ParticipantsIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
1 Poor159151243
2 Fair161222196
3 Good433240412
4 Very good726964343
5 Excellent23392671

Adverse events

Collected over Up to Day 10 (follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)0/173 (0%)0/173 (0%)88/173 (50.9%)
Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)0/168 (0%)0/168 (0%)87/168 (51.8%)
Nurofen Plus®0/169 (0%)0/169 (0%)97/169 (57.4%)
Panadeine® Extra0/113 (0%)0/113 (0%)72/113 (63.7%)
Placebo0/55 (0%)0/55 (0%)35/55 (63.6%)
Most frequent other events
Most frequent other events
EventIbuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlacebo
NauseaGastrointestinal disorders43/17333/16850/16937/11318/55
VomitingGastrointestinal disorders29/17330/16835/16925/11313/55
HeadacheNervous system disorders19/17319/16832/16921/11310/55
DizzinessNervous system disorders12/17315/16823/16914/1133/55
Alveolar osteitisInfections and infestations8/1734/1689/1693/1131/55
Body temperature increasedInvestigations2/1733/1689/1693/1131/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Mean20.2 ± 3.319.8 ± 3.220.1 ± 3.419.7 ± 3.319.8 ± 3.620.0 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Female1051001016833407
Male6868684522271
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
American Indian or Alaska Native012003
Asian3471217
Native Hawaiian or Other Pacific Islander101103
Black or African American4423215
White16515815410751635
More than one race000000
Unknown or Not Reported013105
Region of Enrollment
Region of Enrollment(participants)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
United States17316816911355678
Weight
Weight(kg)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Mean68.1 ± 14.569.0 ± 15.268.8 ± 15.370.8 ± 16.171.0 ± 18.769.2 ± 15.5
Height
Height(cm)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Mean168.5 ± 10.0169.3 ± 10.1169.5 ± 9.8168.5 ± 9.7168.7 ± 9.5168.9 ± 9.9
Drink alcohol
Drink alcohol(participants)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Number6361613615236
Former smoker
Former smoker(participants)Ibuprofen 200mg + Paracetamol 500mg (Lower Dose)Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose)Nurofen Plus®Panadeine® ExtraPlaceboTotal
Number27232013992

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Premier Research
    Austin, Texas 78705, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 9 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2010
First posted
Oct 27, 2010
Start
Jan 2009
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Sep 17, 2018
Last update
Sep 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01229449
Collaborators
Premier Research Group plc, Aptuit
Responsible party
Sponsor
First posted
Oct 27, 2010
Start date
Jan 2009
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Sep 17, 2018
Last update
Sep 17, 2018

Study contacts

Stephen Daniels
principal investigator · Premier Research Group Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Acetaminophen

Start the discussion